BMPR2 mutation and clinical response to imatinib in a case of heritable pulmonary arterial hypertension

10 January 2024

Shine KumarLalitha BiswasAnju Choorakottayil PushkaranRaman Krishna Kumar

https://doi.org/10.1002/pul2.12335

Abstract

Bone morphogenetic protein receptor 2 (BMPR2) mutation is the most common gene mutation implicated in the pathogenesis of pulmonary arterial hypertension (PAH). We describe, for the first time, an excellent clinical response to tyrosine kinase inhibitor imatinib in a patient with heritable PAH from BMPR2 mutation.
accuracy.

Read the full research article

Share:
Additional comments are available to members. Login or register to become a member today